Potent metastasis inhibitor identified

June 22, 2020

By Elizabeth Andrews, Boston Children's Hospital

EurekAlert (press release) - Washington,DC,USA
Researchers at Children's Hospital Boston have isolated a potent inhibitor of tumor metastasis made by tumor cells, one that could potentially be harnessed as a cancer treatment.

Identifying the potential for tamoxifen resistance in patients

June 11, 2020

By American Society for Biochemistry and Molecular Biology (ASBMB)

Tamoxifen is a widely used and highly successful drug in the treatment of breast cancer, though resistance to tamoxifen is still a concern in recurrent disease (affecting 25-35% of patients), since therapy resistant metastatic tumour cells are a major cause of death. In a study in this month's Molecular and Cellular Proteomics, researchers have uncovered a protein profile that may accurately predict whether a cancer will be tamoxifen resistant.

Bevacizumab Added to First-Line Chemotherapy Improves Progression

June 2, 2020

By Emma Hitt

DG News - USA
… the Study Evaluating the Efficacy and Safety of Bevacizumab in Combination With Chemotherapy in Untreated Metastatic Breast Cancer (RIBBON-1) on May 31. …

Small molecule inhibitor shows promise in trastuzumab-resistant metastatic breast cancer

June 1, 2020

By Frank Hoke, Fox Chase Cancer Center

ORLANDO —Fox Chase Cancer Center researchers report that a combination of trastuzumab and neratinib (HKI-272) a novel small molecule inhibitor of the HER2 receptor (ErbB2) appears active in women with HER2-positive metastatic breast cancer who have progressed on previous trastuzumab based therapies. More than one-quarter of the women in a phase I/II trial had their tumors shrink on the combination therapy.